Rate, risk factors and causes of mortality in patients with sjögren's syndrome: A systematic review and meta-analysis of cohort studies

Rheumatology (United Kingdom)

Volumn 55, Issue 3, 2016, Pages 450-460

  Singh, Abha G ^a   Singh, Siddharth ^b   Matteson, Eric L ^a  

^a Division of Rheumatology   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Lymphoma; Mortality; Risk factors; Sj gren's syndrome; Vasculitis

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; LA ANTIBODY;

AGE; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CRYOGLOBULINEMIA; HEMATOLOGIC MALIGNANCY; HUMAN; LYMPHOMA; MORTALITY RATE; MORTALITY RISK; PAROTID ENLARGEMENT; PRIMARY SJOEGREN SYNDROME; PRIORITY JOURNAL; SALIVARY GLAND SCINTISCANNING; SEX DIFFERENCE; SJOEGREN SYNDROME; STANDARDIZED MORTALITY RATIO; SYSTEMATIC REVIEW; VASCULITIS;

EID: 84965058123     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev354     Document Type: Article

References (25)

1. Helmick CG, Felson DT, Lawrence RC et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;58:25-35.
2. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjogren syndrome. Arch Intern Med 2004;164:1275-84.
3. Qin B, Wang J, Yang Z et al. Epidemiology of primary Sjogren's syndrome: a systematic review and metaanalysis. Ann Rheum Dis 2014 Jun 17. pii: annrheumdis-2014-205375. doi: 10.1136/annrheumdis-2014-205375 [Epub ahead of print].
4. Liang Y, Yang Z, Qin B, Zhong R. Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis 2014;73:1151-6.
5. Brito-Zeron P, Kostov B, Solans R, et al. Systemic activity and mortality in primary Sjogren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. Ann Rheum Dis 2014 Nov 28. pii: annrheumdis-2014-206418. doi: 10.1136/annrheumdis-2014-206418 [Epub ahead of print].
6. Nannini C, Jebakumar AJ, Crowson CS, Ryu JH, Matteson EL. Primary Sjogren's syndrome 1976-2005 and associated interstitial lung disease: a population-based study of incidence and mortality. BMJ Open 2013;3:e003569.
7. Thomas E, Symmons DPM, Brewster DH, Black RJ, Macfarlane GJ. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol 2003;30:958-65.
8. Alamanos Y, Tsifetaki N, Voulgari PV et al. Epidemiology of primary Sjogren's syndrome in north-west Greece, 1982-2003. Rheumatology 2006;45:187-91.
9. Horvath IF, Szanto A, Papp G, Zeher M. Clinical course, prognosis, and cause of death in primary Sjogren's syndrome. J Immunol Res 2014;2014:647507.
10. Routsias JG, Goules JD, Charalampakis G et al. Malignant lymphoma in primary Sjogren's syndrome: an update on the pathogenesis and treatment. Semin Arthritis Rheum 2013;43:178-86.
11. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses:the PRISMA statement. Ann Intern Med 2009;151:264-9, W64.
12. Wells GA, Shea B, O'Connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa, ON: Ottawa Hospital Research Institute; 2011. http://www.ohri.ca/ programs/clinical-epidemiology/oxford.asp.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
15. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
16. Brito-Zeron P, Ramos-Casals M, Bove A, Sentis J, Font J. Predicting adverse outcomes in primary Sjogren's syndrome:identification of prognostic factors. Rheumatology 2007;46:1359-62.
17. Ioannidis JPA, Vassiliou VA, Moutsopoulos HM. Longterm risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum 2002;46:741-7.
18. Pertovaara M, Pukkala E, Laippala P, Miettinen A, Pasternack A. A longitudinal cohort study of Finnish patients with primary Sjogren's syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis 2001;60:467-72.
19. Theander E, Manthorpe R, Jacobsson LTH. Mortality and causes of death in primary Sjogren's syndrome: a prospective cohort study. Arthritis Rheum 2004;50:1262-9.
20. Weng MY, Huang YT, Liu MF, Lu TH. Incidence and mortality of treated primary Sjogren's syndrome in Taiwan: a population-based study. J Rheumatol 2011;38:706-8.
21. Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
22. Nishishinya MB, Pereda CA, Munoz-Fernandez S et al. Identification of lymphoma predictors in patients with primary Sjogren's syndrome: a systematic literature review and meta-analysis. Rheumatol Int 2015;35:17-26.
23. Ramos-Casals M, Brito-Zeron P, Yague J et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome. Rheumatology 2005;44:89-94.
24. Voulgarelis M, Ziakas PD, Papageorgiou A et al. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjogren syndrome. Medicine 2012;91:1-9.
25. Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum 2000;29:296-304.